| MiR423-5p as a circulating biomarker for heart failure AJ Tijsen, EE Creemers, PD Moerland, LJ de Windt, AC van der Wal, ... Circulation research 106 (6), 1035-1039, 2010 | 849 | 2010 |
| Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk FA Van Nimwegen, M Schaapveld, CPM Janus, ADG Krol, EJ Petersen, ... JAMA internal medicine 175 (6), 1007-1017, 2015 | 502 | 2015 |
| High risk of symptomatic cardiac events in childhood cancer survivors HJ Van Der Pal, EC Van Dalen, E Van Delden, IW Van Dijk, WE Kok, ... Journal of clinical oncology 30 (13), 1429-1437, 2012 | 370 | 2012 |
| Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study EC van Dalen, HJH van der Pal, WEM Kok, HN Caron, LCM Kremer European journal of cancer 42 (18), 3191-3198, 2006 | 342 | 2006 |
| Management of chronic heart failure guided by individual N-terminal pro–B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided … LWM Eurlings, PEJ van Pol, WE Kok, S van Wijk, ... Journal of the American College of Cardiology 56 (25), 2090-2100, 2010 | 242 | 2010 |
| Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study HJ van der Pal, EC van Dalen, M Hauptmann, WE Kok, HN Caron, ... Archives of internal medicine 170 (14), 1247-1255, 2010 | 223 | 2010 |
| Histopathologic validation of intracoronary ultrasound imaging RJG Peters, WEM Kok, MG Havenith, H Rijsterborgh, AC van der Wal, ... Journal of the American Society of Echocardiography 7 (3), 230-241, 1994 | 175 | 1994 |
| A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European … K Salah, WE Kok, LW Eurlings, P Bettencourt, JM Pimenta, M Metra, ... Heart 100 (2), 115-125, 2014 | 163 | 2014 |
| NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy … S Stienen, K Salah, AH Moons, AL Bakx, P van Pol, RAM Kortz, ... Circulation 137 (16), 1671-1683, 2018 | 157* | 2018 |
| Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction K Salah, S Stienen, YM Pinto, LW Eurlings, M Metra, A Bayes-Genis, ... Heart 105 (15), 1182-1189, 2019 | 156 | 2019 |
| Coronary atherosclerosis within a myocardial bridge, not a benign condition RJ de Winter, WEM Kok, JJ Piek Heart 80 (1), 91-93, 1998 | 133 | 1998 |
| Prediction of Restenosis After Coronary Balloon Angioplasty: Results of PICTURE (Post–IntraCoronary Treatment Ultrasound Result Evaluation), a Prospective Multicenter … RJG Peters, WEM Kok, C Di Mario, PW Serruys, FWHM Bär, ... Circulation 95 (9), 2254-2261, 1997 | 98 | 1997 |
| Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial JJ Brugts, SP Radhoe, PRD Clephas, D Aydin, MWF Van Gent, ... The Lancet 401 (10394), 2113-2123, 2023 | 90 | 2023 |
| Risk and temporal changes of heart failure among 5‐year childhood cancer survivors: a DCOG‐LATER study EAM Feijen, A Font‐Gonzalez, HJH Van der Pal, WEM Kok, RB Geskus, ... Journal of the American Heart Association 8 (1), e009122, 2019 | 90 | 2019 |
| Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch … JJM Kwakman, LHJ Simkens, L Mol, WEM Kok, M Koopman, CJA Punt European Journal of Cancer 76, 93-99, 2017 | 73 | 2017 |
| Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines EC van Dalen, HJH van der Pal, C van den Bos, WEM Kok, HN Caron, ... European Journal of Cancer 42 (15), 2549-2553, 2006 | 66 | 2006 |
| Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure K Salah, WE Kok, LW Eurlings, P Bettencourt, JM Pimenta, M Metra, ... JACC: Heart Failure 3 (10), 751-761, 2015 | 65 | 2015 |
| The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors E Sieswerda, A Postma, EC van Dalen, HJH van der Pal, WJE Tissing, ... Annals of oncology 23 (8), 2191-2198, 2012 | 64 | 2012 |
| Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study P Knaapen, WG van Dockum, MJW Götte, KA Broeze, AC van Rossum, ... Journal of nuclear cardiology 13, 660-667, 2006 | 49 | 2006 |
| Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects … MJ Ehrhardt, JM Leerink, RL Mulder, A Mavinkurve-Groothuis, W Kok, ... The Lancet Oncology 24 (3), e108-e120, 2023 | 45 | 2023 |
